Anti–CTLA‐4 synergizes with dendritic cell–targeted vaccine to promote IL‐3–dependent CD4 + effector T cell infiltration into murine pancreatic tumors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti–CTLA‐4 synergizes with dendritic cell–targeted vaccine to promote IL‐3–dependent CD4
+
effector T cell infiltration into murine pancreatic tumors
Authors
Keywords
-
Journal
Annals of the New York Academy of Sciences
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-04-04
DOI
10.1111/nyas.14049
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging strategies for combination checkpoint modulators in cancer immunotherapy
- (2018) Aleksandra Popovic et al. JOURNAL OF CLINICAL INVESTIGATION
- Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4
- (2018) Sergio A. Quezada et al. CLINICAL CANCER RESEARCH
- Immunotherapy transforms cancer treatment
- (2018) Neeha Zaidi et al. JOURNAL OF CLINICAL INVESTIGATION
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of CD86 on Human Islet Endothelial Cells Facilitates T Cell Adhesion and Migration
- (2014) B. Lozanoska-Ochser et al. JOURNAL OF IMMUNOLOGY
- Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
- (2012) Maria Grazia Ruocco et al. JOURNAL OF CLINICAL INVESTIGATION
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-3 is a novel target to interfere with tumor vasculature
- (2011) P Dentelli et al. ONCOGENE
- Modulation of the "blood-tumor" barrier improves immunotherapy
- (2010) Mitali Manzur et al. CELL CYCLE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inducing CTLA-4-Dependent Immune Regulation by Selective CD28 Blockade Promotes Regulatory T Cells in Organ Transplantation
- (2010) N. Poirier et al. Science Translational Medicine
- The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC-205/CD205 Receptor on Dendritic Cells
- (2009) Bei Wang et al. Annals of the New York Academy of Sciences
- Endothelin B Receptor, a New Target in Cancer Immune Therapy
- (2009) L. E. Kandalaft et al. CLINICAL CANCER RESEARCH
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
- (2008) A. Ribas et al. CLINICAL CANCER RESEARCH
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
- (2008) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells
- (2008) Rachael A. Clark et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome
- (2008) H. Lin et al. SCIENCE
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started